报价延迟最少15分钟:2025/07/20 13:12 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.62 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.04/--
|
|
企业价值
72.82M
|
| 资产负债 |
|
每股账面净值
3.21
|
| 现金流量 |
|
现金流量率
0.03
|
| 损益表 |
|
收益
26.49M
|
|
每股收益
1.74
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 13:12 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment. |
